Clinical Research Grants support hypothesis-driven clinical research projects that have significant potential to advance our understanding of Dravet syndrome; slow or halt the of progression of the disease, characteristics, or comorbidities of the disease; and/or reduce mortality. This research will be patient-oriented research in which an investigator directly interacts with human subjects/patients. Such studies may be conducted in conjunction with laboratory-based research, as appropriate. This includes studies such as therapeutic interventions or clinical trials.
Award funds of $150,000 for two years ($75,000 per year) are made to the affiliated institution in four payments, the second of which is dependent on IRB approval if not required for the first portion of the funding period. Awards are to be used to support a minimum physician effort (salary and benefits) of 25%; funds may also be used to support a clinical trial specialist’s efforts or similar. Up to $1000 may be set aside to present findings at a national meeting. No indirect costs are permitted. Submission of scientific and financial reports are due no later than 30 days after completion of the project.
Successful applicants hold an MD or DO degree, have a valid US medical license (though US citizenship is not required), work full-time at a US academic institution that grants doctoral degrees, and are guaranteed a minimum of 75% research time at their institution, though not all of that effort is expected on this project. With the exception of career development and training awards, Principal Investigators on NIH grants exceeding $225,000 and recipients of other fellowships are not eligible.
Investigators applying for a clinician-research grant should ensure their proposed project addresses the needs of the Dravet syndrome community and DSF’s mission to support research toward better treatments and a cure for Dravet syndrome.
Tags: Dravet Syndrome, SCN1A
Mary Anne Meskis